Evidence map›Paper›PMID 31285681›Full record

ArticleCurrent oncology (Toronto, Ont.)2019

Renal cell carcinoma in the Canadian Indigenous population.

E C L Wong, R H Breau, R Mallick, L Wood, F Pouliot, N S Basappa, S Tanguay, D Soulières, A So, D Heng and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

E C L WongDepartment of Surgery, McMaster University, Hamilton, ON.
R H BreauDepartment of Surgery, University of Ottawa, Ottawa, ON.
R MallickOttawa Methods Centre, The Ottawa Hospital Research Institute, Ottawa, ON.
L WoodDepartment of Medicine, Dalhousie University, Halifax, NS.
F PouliotDepartment of Surgery, Université Laval, Quebec City, QC.
N S BasappaDepartment of Medicine, University of Alberta, Edmonton, AB.
S TanguayDepartment of Surgery, McGill University, Montreal, QC.
D SoulièresDepartment of Surgery, Université de Montréal, Montreal, QC.
A SoDepartment of Surgery, University of British Columbia, Vancouver, BC.
D HengDepartment of Medicine, University of Calgary, Calgary, AB.
L T LavalléeDepartment of Surgery, University of Ottawa, Ottawa, ON.
D DrachenbergDepartment of Surgery, University of Manitoba, Winnipeg, MB.
A KapoorDepartment of Surgery, McMaster University, Hamilton, ON.
McMaster University · CAUniversity of Ottawa · CADalhousie University · CAMcGill University · CAOttawa Hospital · CAUniversité de Montréal · CAUniversité Laval · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diagnosis and treatment of renal cell carcinoma (rcc) might be different in Indigenous Canadians than in non-Indigenous Canadians. In this cohort study, we compared rcc presentation and treatments in Indigenous and non-Indigenous Canadians. Methods: Patients registered in the Canadian Kidney Cancer Information System treated at 16 institutions between 2011 and 2018 were included. Baseline patient, tumour, and treatment characteristics were compared between Indigenous and non-Indigenous Canadians. The primary objective was to determine if differences in rcc stage at diagnosis were evident between the groups. The secondary objective was to determine if treatments and outcomes were different between the groups. Results: During the study period, 105 of the 4529 registered patients self-identified as Indigenous. Those patients were significantly younger at the time of clinical diagnosis (57.9 ± 11.3 years vs. 62.0 ± 12.1 years, Conclusions: Compared with their non-Indigenous counterparts, Indigenous Canadian patients with rcc are diagnosed at an earlier age and at a similar clinical stage. Despite higher baseline comorbid conditions, clinical outcomes are not worse for Indigenous Canadians than for non-Indigenous Canadians.

Indexed as

AgedCanadaCarcinoma, Renal CellCohort StudiesComorbidityDiabetes MellitusFemaleHumansHypertensionIndigenous PeoplesKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedNeoplasm StagingProportional Hazards ModelsdiagnosisIndigenous CanadiansoutcomesRenal cell carcinomatreatment

Identifiers

PMID31285681
PMCPMC6588075
OpenAlexW2954386514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.